Here are the DEF 14A proxy statements from Ironwood Pharmaceuticals, Inc. (IRWD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IRWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRWD filings page.
Ironwood Pharmaceuticals is asking stockholders to approve four items at its virtual 2026 annual meeting on June 16, 2026 at 9:00 a.m. Eastern. Investors will vote on electing eight directors to one‑year terms, an advisory say‑on‑pay vote, and ratifying KPMG LLP as 2026 auditors.
A key proposal seeks to amend the Amended and Restated 2019 Equity Incentive Plan to add 10,000,000 more shares for equity awards. The proxy describes a largely independent board, detailed committee structure, director fees and stock‑based retainers, and a pay‑for‑performance program using cash bonuses and PSU/RSU equity tied to total stockholder return.